DAANCE FOR CHEMOTHERAPY-INDUCED NEUROPATHY
Recruiting
Phase 2
Interventional Study
Cancer of the Breast
Chemotherapy-induced Neuropathy
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 40 and older
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Supportive Care
- Participants needed
- 140 (estimated)
- Sponsor
- Ohio State University Comprehensive Cancer Center · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Up to 80% of breast cancer survivors experience chemotherapy-induced neuropathy that impairs quality of life and increases fall risk long into survivorship, yet treatment options for neuropathy remain limited. The successful treatment will target neurophysiologic mechanisms for restoring function while addressing patient-reported symptoms and participation in treatment. Toward this end, the invest…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Breast Cancer (BC) diagnosis of Stage I-IV including metastatic disease
* completed taxane-based chemotherapy for BC at least 3 months ago (no limit on how long ago)
* symptomatic for chemotherapy-induced neuropathy (self-report)
* postural control score that indicates potenti…
Contacts